Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 3 October 2017, 14:11 HKT/SGT
Share:
    

Source: Eisai
Sato Pharmaceutical and Eisai to Co-Promote New Oral Antifungal Agent Containing Active Ingredient Fosravuconazole in Japan

TOKYO, Oct 3, 2017 - (JCN Newswire) - Sato Pharmaceutical Co., Ltd., Eisai Co., Ltd., and Seren Pharmaceuticals Inc. announced today that Sato Pharma and Eisai will co-promote a new triazole class oral antifungal agent (development code: BFE1224, "the agent") containing the active ingredient fosravuconazole L-lysine ethanolate ("fosravuconazole") in Japan, based on an agreement between the three companies. The agent is currently under regulatory review for the treatment of onychomycosis.

After receiving regulatory approval, Sato Pharma will begin distributing the agent, and Sato Pharma and Eisai will jointly provide information on its proper use.

Fosravuconazole is a new oral antifungal component developed by Eisai. In 2010, Eisai concluded a license agreement with Seren Pharma (formerly known as "Brain Factory Co., Ltd."), granting them exclusive rights to develop, commercialize, and sublicense the agent in Japan. In 2014, Seren Pharma concluded an agreement with Sato Pharma, granting them the development and commercialization rights, and both companies continued to develop the agent for treating onychomycosis. In January 2017, Sato Pharma applied for marketing authorization for the agent.

Sato Pharma, Eisai, and Serena Pharma will cooperate to maximize the value of fosravuconazole in order to fulfil the unmet medical needs of patients with fungal diseases.

About fosravuconazole

Fosravuconazole is a new oral antifungal component developed by Eisai. Fosravuconazole is a prodrug that improves the solubility and bioavailability of ravuconazole, the main active ingredient. When administered to humans, it is rapidly converted to ravuconazole. Ravuconazole demonstrates antifungal activity by inhibiting ergosterol biosynthesis, a membrane component of fungal cells.

About onychomycosis

Onychomycosis is a fungal infection of the toenails or fingernails. Pathogens enter the skin through the small separations between the nail and the nail bed, and eventually infect the nail itself. It is a common nail disease, with an estimated approximately 11 million sufferers in Japan. While not life-threatening, it is an important public health issue, as if left untreated, it causes local tenderness due to deformation and thickening of the nails, limits physical activity due to pain, can spread to family members, and can lead to an outbreak of secondary fungal and bacterial infections. Early treatment of onychomycosis is necessary to prevent loss of QOL (Quality of Life).

About Sato Pharmaceutical Co., Ltd.

Sato Pharmaceutical Co., Ltd., operating under it's corporate philosophy of "Healthcare Innovation", is a pharmaceutical company that provides effective, safe, and highquality products for practicing selfcare, while always keeping the health of its customers in mind. In addition to its main consumer healthcare business, Sato Pharmaceutical also develops and provides highly original products primarily in the field of dermatology.

For more information about Sato Pharmaceutical Co., Ltd., please visit, www.sato-seiyaku.co.jp/company/en/index.html.

About Seren Pharmaceuticals Inc.

Seren Pharmaceuticals is a specialized R&D-based pharmaceutical company which in-licenses pharmaceutical candidates for which POC (Proof of Concept) has already been established but development has stalled due to low-development priority, despite high medical needs and commercial potential. Seren Pharmaceuticals makes use of in-house specialist groups and networking to conduct drug discovery and in-licensing from a fresh perspective, and through efficient development, expediates commercialization.

For more information about Seren Pharmaceuticals Inc., please visit www.serenpharma.com.


About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Oct 3, 2017 14:11 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2017 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Oct 13, 2017 09:48 HKT/SGT
Eisai: Transfer of Rights to Anti-Rheumatic Agent Kolbet Tablets 25mg in Japan
Oct 11, 2017 11:48 HKT/SGT
Small and Easy to Take, Just One Tablet per Dose Eisai to Launch "Onji-No-Megumi" for Improving Forgetfulness in Middle Age and Beyond
Oct 4, 2017 09:49 HKT/SGT
Eisai and Biotoscana Sign Exclusive Licensing Agreement for Latin America
Sept 29, 2017 15:12 HKT/SGT
Eisai Presents Results of Phase Iii Trial of Lenvima (Lenvatinib) in Unresectable Hepatocellular Carcinoma in Oral Session at 20th CSCO Annual Meeting
Sept 27, 2017 12:25 HKT/SGT
Eisai: Application for Additional Indication of Lenvima for Hepatocellular Carcinoma Accepted for Review by U.S. FDA
Sept 22, 2017 15:46 HKT/SGT
Eisai: Additional Dosage and Administration of Proton Pump Inhibitor Pariet 5 mg Tablets, 10 mg Tablets Approved in Japan for Maintenance Therapy of Proton Pump Inhibitor Resistant Reflux Esophagitis
Sept 22, 2017 09:56 HKT/SGT
Eisai Presents Latest Non-Clinical Data on Its First Antibody-Drug Conjugate MORAb-202 at 8th Annual World ADC
Sept 19, 2017 09:01 HKT/SGT
Eisai Presents Results of Phase Iii Clinical Study of Lenvima (Lenvatinib) in Unresectable Hepatocellular Carcinoma at 11th ILCA Annual Conference
Sept 13, 2017 13:25 HKT/SGT
Eisai to Launch New "Etak Antimicrobial Spray Alpha" Containing Long-Acting Antimicrobial Agent Etak
Sept 12, 2017 23:06 HKT/SGT
Eisai and Mamorio to Jointly Launch "Me-Mamorio" Tracking Tool to Support People with Dementia and Seniors Going Out
More news >>
 News Alerts
Copyright © 2017 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: